Free Trial
→ Nvidia CEO Makes First Ever Tesla Announcement (From Brownstone Research) (Ad)tc pixel

PureTech Health (LON:PRTC) Trading Up 14.2% - What's Next?

Written by MarketBeat
Updated September 22, 2025
PureTech Health logo with Medical background

Key Points

  • PureTech Health's shares rose by 14.2% in trading, reaching a high of GBX 123.80 ($1.67) before closing at GBX 121.50 ($1.64), with trading volume significantly increasing to 9,013,305 shares.
  • The company has a market capitalization of £293.65 million and operates with a high P/E ratio of 714.71, along with a debt-to-equity ratio of 45.82.
  • Insider buying activity was reported, with Bharatt Chowrira purchasing 167,739 shares at an average price of GBX 1, totaling £1,677.39.
  • Interested in PureTech Health? Here are five stocks we like better.

PureTech Health plc (LON:PRTC - Get Free Report)'s share price rose 14.2% during trading on Saturday . The company traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). Approximately 9,013,305 shares changed hands during trading, an increase of 1,053% from the average daily volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Price Performance

The company has a fifty day simple moving average of GBX 129.31 and a two-hundred day simple moving average of GBX 129.65. The stock has a market capitalization of £303.07 million, a price-to-earnings ratio of 737.65 and a beta of 1.02. The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68.

Insider Transactions at PureTech Health

In other news, insider Bharatt Chowrira bought 167,739 shares of the firm's stock in a transaction on Thursday, July 3rd. The shares were purchased at an average cost of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is owned by insiders.

PureTech Health Company Profile

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Featured Stories

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.